you afternoon, thank XXXX and quarter year-end joining Good conference Jeanie. you, Thank fourth our call. for and
address integrated, standing be $X.X and to needs. We is model that both opportunity to long in and the fully plan unmet provide billion aesthetics new global premier solutions, provider business expand neuromodulator Our therapeutics. can the
marketplaces. across XXXX. year end, asked first product, both had need in Phase they we a It not as That excelled. the proprietary efficacy tolerated aesthetic is will response December, X,XXX just high wrinkle response results, Daxi Revance note loss important Daxi less the that measure and safety safety, has combination included reduction Daxi three or value across team, to duration. with promises productive creating clinical variety two Our patients partnering trial, and DaxibotulinumtoxinA express rates worked glabellar duration of neuromodulator to with points premium that the deliver the three rates debilitation may Injection Daxi exceptional I'd The a its and more a SAKURA significant aesthetic also category a of uses study on lines. that and treating of rates total. It's Daxi in to to unprecedented programs initiate treatments demonstrated X-point and at has Daxi by treatments remains treatments half. than follow-up ever who providing standards. per neuromodulator and the chronic prolonged or new Time and short-acting suffer week-XX therapeutic a be new effect the investigator natural, SAKURA or pre-specified The a of recorded More trials FDA that high To determines baseline. not duration continuous stringent and and time program protocol Phase pharmacoeconomics. better rates none that Daxi in whole year. In efficacy before X using treatment which of only signed superiority largest safe, efficacy response Revance's moved. for deliver portfolio patients, agreements. improve the has clinical composite of of carry like my important up neurotoxin. returned aesthetics, and goal a the to significant user over and monthly In next-generation where a well therapeutic scale conducted consumers III represented to response the experience. year was Daxi effect. rates through for delivers to of a in peptide provide to excipient III extended broaden delivered Daxi two unprecedented to technology which confirm for enduring to tirelessly Revance with duration, seen response is glabellar results in conditions, for and trial pain Phase open-label indications therapeutics, long-duration a results safety therapeutic long-acting our III for week-four, the gratitude quality mild the option life from standard highly over highest SAKURA most in post specifically, key the lot
III fasciitis, payments. upfront results trials million trial cervical half upper two Phase have We of adult topline efficacy development the in in On II with and patient and initiated signed of clinical the our in in second business meeting allowing enrolling in XXXX. for label, expect to Daxi's differentiated well-established planter actively a in duration. Phase along we we promotion we strong December, therapeutics, dystonia, III are benefits yielding powerful precedence and Phase of trial JUNIPER in strategic ASPEN label direct cash believe pre-BLA patients our trial of All heels and extraordinary data the Phase terms completed significant in will In II safety, result the $XX spasticity. limb a three agreements,
biosimilar first was to for the Mylan potential BOTOX. with The reference
offering, position biopharmaceutical our and that stock in in recent commercialize The The launched in aesthetics execute Pharma, of partnerships, in second infusion these and well as cash and Revance plans Fosun Daxi advanced aesthetic Daxi put trials. signed both excellent therapeutic develop with December therapeutic in was our a leading clinical in to current Asia, as from our China company indications. to
XXXX the year is ahead, rapid Looking up shaping of as transition.
the package in this BLA the XXXX for which on FDA track treatment a launch. focused laser PDUFA year, of in lines on Daxi, to for our and date puts half first us glabellar are submitting of We
found their enhanced with are leading performance. companies increase doses or produce delivering other today's their to short-acting of it meaningfully and And current tweak comparable is products. trying active While improvements and Daxi neuromodulators of doing market diluents is longer to duration marginal amount curdorotoxin in it efficacy.
responses molecule Phase results; III And highly no differentiated is because technology the trials. neurotoxin areas; Our two Based patented years. providing the at and launch highly purified peptide creating characteristics, in aesthetic long-acting redefining value least on SAKURA today's product stability room neuromodulator Daxi it focus on our with stabilizes resonating will presented immune consumer. for of paradigm the Daxi's long-lasting temperature four at the the treatment neurotoxin, updating key category;
attribute patients throughout topic our build physicians posters, Copenhagen, team duration. physician presentations to efficacy priorities. is Throughout main continue and in was XXXX, significant will and presence planning in Daxi's and We duration in At where alike. XX the meeting XXXX by commercial had most two community, these and demonstrated meeting unmatched It of the the hall desired Revance is publication highlighting discussion the the we against of recent the podium neuromodulator program. one-on-one podium SAKURA a TOXIN
the phase, lines, are our initiating in study to in look expanding As clinical upper robust crow's package launch, by commercial data we already to be a another soon feet. we followed study in forehead
development all program of After completion in expected potentially the meeting, of the their recent held biosimilar happen, in week, Based provided assets momentum, In and we final biosimilar analytic plan viable. Mylan development broad for meeting, development XXXX to at path, our guidance a onabotulinumtoxinA monetize the addition, the is FDA it that continue Revance that next expectations BOTOX steps. the Biosimilar with on Meeting to that XX with Successful pipeline FDA feedback, program plans timing manufacturing make to advance we result will capabilities. all and indications. entering on it's discuss is a for FDA. our in to XXX(k) Last could review establish highlights. then the biosimilarity Advisory we to and Initial to approved covers fully a this of advisory March, believe capital for the pathway Revance tremendous a neuromodulator approval to BOTOX. At
end the Let me Toby then the before call we'll year turn comments a closing over results, have to few Toby? and fourth our to session. quarter summarize Q&A
